Ultragenyx reports early success with Angelman syndrome drug, backing up 2022 acquisition
Ultragenyx has found early success with its experimental treatment for the rare disease Angelman syndrome.
Ultragenyx has found early success with its experimental treatment for the rare disease Angelman syndrome.
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michelle Hughes, MD Over the past two decades, there has been an increasing need for GI hospitalists…
Researchers discuss the striking link between high blood levels of TMAO and chronic kidney disease risk over time.
All Lord of the Rings fans should get excited about the new LEGO set themed on Barad-dûr, Sauron’s iconic stronghold. The 5,471-piece set features the…
Increasingly, nurse practitioners and physician assistants are joining cardiology, dermatology, and other specialty practices, broadening their skills and increasing their income. This development worries some…
https://youtu.be/wThmg8Ezm9w Earlier this year, Dutch Drone Gods, in partnership with Red Bull, unveiled the World’s Fastest Drone that went head-to-head with Max Verstappen behind the…
Medical extended reality (XR) has the potential to improve your health care. XR devices deliver new types of treatments and tools for diagnosis in health…
Unless you are Elon Musk and believe chess is “too simple to be useful in real life,” you know, chess is a strategic and competitive…
With the right information and support, women living with PCOS can manage their condition and lead healthy lives. Learn more with the AMA.
Check out this quiz on the NKF’s KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for protein and energy…
Onfray et al. report the comparison of hTSCs, hTELCs, and primed, extended, and naive hPSCs by transcriptomics, proteomics, DNAme quantification, X, and metabolic activity. TELCs have…